A Convergent Total Synthesis of the Kedarcidin Chromophore: 20-Years in the Making

Martin J. Lear^{*,[a,b]}, Keiichiro Hirai^[b], Kouki Ogawa^[b], Shuji Yamashita^[b], and Masahiro Hirama^{*,[b,c,d]}

Dedicated to Professor Samuel J. Danishefsky for his outstanding contributions to the total synthesis of highly complex and biologically important natural products

[a] School of Chemistry, University of Lincoln, Brayford Pool, Lincoln, Lincolnshire, LN6 7TS (United Kingdom). E-mail: mlear@lincoln.ac.uk

[b] Department of Chemistry, Graduate School of Science, Tohoku University, Aza Aramaki, Aoba-ku, Sendai 980-8578 (Japan).

[c] Research and Analytical Center for Giant Molecules, Graduate School of Science, Tohoku University, Sendai 980-8578 (Japan).

[d] Current address: Acro-Scale, Inc., 3-8-1-F7 Kokubuncho, Sendai 980-0803, Japan. E-mail: hirama@m.tohoku.ac.jp

Abstract: The kedarcidin chromophore is a formidable target for total synthesis. Herein, we describe a viable synthesis of this highly unstable natural product. This entailed the early introduction and gram-scale synthesis of 2-deoxysugar conjugates of both L-mycarose and L-kedarcosamine. Key advances include: (1) stereoselective allenylzinc keto-addition to form an epoxyalkyne; (2) α -selective glycosylations with 2-deoxy thioglycosides (AgPF₆/DTBMP) and Schmidt donors (TiCl₄); (3) Mitsunobu aryl etherification to install a hindered 1,2-*cis*-configuration; (4) atropselective and convergent Sonogashira-Shiina cyclization sequence; (5) Ohfuné-based amidation protocol for naphthoic acid; (6) Ce(III)-mediated nine-membered enediyne cyclization and ester/mesylate derivatisation; (7) SmI₂-based reductive olefination and global HF-deprotection end-game. The longest linear sequence from gram-scale intermediates is 17-steps, and HRMS data of the synthetic natural product was obtained for the first time.

Introduction

Total synthesis is a challenging field. Even more so if the natural product is complex in structure and non-obvious in construction. The ensuing challenge reach unprecedented levels when the natural product is highly unstable. Even more so, if late-stage synthetic precursors are equally unstable. Very few natural products have been tackled under such criteria. Outstanding cases in the antitumor antibiotic field include the ten- and nine-membered cyclic enediynes.^{1–6} Complexity aside, the latter enediynes are arguably more challenging to make because of increased ring-strain.^{7–13} A case in point is the kedarcidin chromophore (**1**, Figure 1). This nine-membered cyclic enediyne exists kinetically stabilized in Nature as part of its chromoprotein complex, kedarcidin.^{14,15} The enediyne **1**, for example, decomposes within 1–2 h at room temperature once separated from its non-covalently bound apoprotein, even in aprotic solvents. Notably, nine-membered bicyclic enediynes like **1** readily undergo both spontaneous and nucleophile-induced cycloaromatizations via highly reactive *p*-benzyne diradical species to give aromatized benzenoid products,^{16–18} some of which are more readily isolated and synthesized in stable cyclized forms on the bench.^{19–23}

Kedarcidin itself was first discovered in 1990 by Bristol-Myers Squibb. It was identified as a cytotoxic product from the supernatant of an unknown microbe cultured from a soil sample collected in the Maharashtra State of India. In 1991, the company disclosed the product (kedarcidin) to be a new potent, chromoprotein antitumor antibiotic.^{24,25} The producing organism was eventually designated to be an actinomycete strain L585-6 of uncertain

taxonomy. Today, the genus is likely to be *Streptoalloteichus* sp. ATCC 53650 (not *Saccharothrix*). This particular species has recently been shown to produce kedarcidin. Gene sequencing has also shown ATCC 53650 to contain all of the biosynthetic machinery necessary to construct the kedarcidin chromophore (**1**).²⁶

¹ H HMR	natural 1	synthetic 1'	aglycon 2
H10	(d, 5.4 Hz)	(s)	(d, 5.6 Hz)
H11	(dd, 5.4, 3.3 Hz)	(d, 3.0 Hz)	(dd, 5.6, 2.8 Hz)
H12	(d, 3.3 Hz)	(d, 3.0 Hz)	(d, 2.8 Hz)

Figure 1. Structural revisions and numbering system of the kedarcidin chromophore (**1**).

During 1992-1994, the bioactivities and structures of the isolated chromophore (**1**) and apoprotein of kedarcidin were further elucidated by Leet and colleagues within Bristol-Myers Squibb.²⁷⁻²⁹ Like other chromoprotein antitumor antibiotics, kedarcidin elicits an extraordinary ability to drive an astonishing sequence of histone/DNA recognition and peptide/nucleotide cleavage events.¹⁻¹² The acidic apoprotein of kedarcidin is proposed to first associate and enzymatically cleave the basic histone-coiled proteins.³⁰ Subsequent exposure of chromosomal DNA, release of the enediyne core (**1**), naphthyl-based DNA intercalation, 5'-TCCTN-3' sequence recognition, and Masamune-Bergman cycloaromatization of **1**, thereby generates a p-benzyne diradical that is transiently and non-covalently bound to DNA. This latter species then initiates DNA-strand breaking and crosslinking events via hydrogen abstraction of the deoxyribose backbone. These oxidative events consequently trigger cell death via the generation of carbon-centered radicals and radical oxygen species (ROS). Despite this non-trivial sequence of events, kedarcidin still elicits potent, yet selective in vivo antitumor activity against P388 leukemia and B16 melanoma cells.

Equally eventful and non-trivial has been the structural elucidation of the kedarcidin chromophore (**1**). To date, extensive NMR, MS/MS, chemical degradation, derivatization, reductive, radical-trapping, biosynthetic and total synthesis studies have provided convincing evidence for the enediyne structure **1**. In 1993, Leet et al. described in full their seminal

characterization studies of the chromophore structure.²⁸ They first proposed an azatyrosyl α -amino motif about the *ansa*-macrolide bridge (Figure 1). In 1997, we updated the whole structure to be antipodal and demonstrated the chromophore to be a β -amino acid derived *ansa*-macrolide (**1'**).³¹ It is noteworthy that the amino-mutase to achieve such a β -amino motif has only recently been characterized.³² In 2007, Myers and coworkers completed an impressive total synthesis of this 1997-structure **1'**.³³ Comparison of natural and synthetic ¹H NMR data, nevertheless, indicated the C10- α -epimeric stereoconfiguration of **1'** should be inverted to **1**.

In 2009, we provided strong NMR spectroscopic evidence for Myers' C10- β -epimer **1** through the synthesis of the complete aglycon **2** of the kedarcidin chromophore in protected form.³⁴ The currently accepted target for synthesis is thus Myers' structure **1**. Herein, we report a detailed account of our early-stage incorporation of both kedarcidin sugars (as elaborate *O*-protecting groups) and the convergent construction of the multicyclic, fully functionalized cyclic epoxyenediynes core. Collectively, our efforts have led to the development of a viable total synthesis of **1** as characterised by HRMS. Product instabilities have, however, prevented clean NMR characterization of the cyclic enediyne material in unprotected form.

Results and Discussion

Scheme 1. General total synthesis plan for the kedarcidin chromophore (**1**).

In previous studies to the kedarcidin aglycon **2**, we secured several enantioselective routes to gram quantities of all key fragments: epoxy-iodocyclopentene **3**, aza- β -tyrosine **4**, alkyne-polyol **5**, and naphthoic acid **6** (Scheme 1).^{31,34–38} We also determined practical methods to synthesize the 2-deoxy sugars, L-mycarose **7** and L-kedarnosamine **8**.³⁹ Not only this, but we developed and achieved the direct α -selective glycosylation of several advanced C10- α -epimeric aglycon precursors to **1'**.^{33,40,41} The key question now was when to incorporate the kedarcidin sugars into our general synthesis plan (Scheme 1). The C4/C5-dioxy, epoxybicyclo[7.3.0]-dodecenediynes frameworks like **10** and **11** are known to be exceedingly

unstable.³⁴ Among other decomposition possibilities, such frameworks are prone to undergo facile oxy-Cope ring openings to afford bis-allenyl species.³⁷ The question thus came down to incorporating the sugars at an early or late stage *en route* to making **9**. Importantly, these glycosylation events should be executed before cyclization into a highly labile, nine-membered ring system like **10**. In either case, the efficiency and α -stereoselectivity of our current glycosylation protocols^{40,41} needed to be tested on newly functionalized substrates of unknown reactivity (cf. **3**, **5**, and **9**).

Scheme 2. Synthesis of late-stage, C10- α -epimeric aglycon acceptors **18** (for L-mycarose) and **19** (for L-kedarasamine).

At first, a late-stage glycosylation strategy was investigated. The *ansa*-macrolides **18** and **19** (akin to **9**) were thus targeted as suitable L-mycarose and L-kedarasamine acceptors, respectively (Scheme 2). Treatment of **5** with 2,2-dimethoxypropane and acetyl deprotection afforded the acetonido-alkyne **12** in 76% yield, 2 steps. Sonogashira coupling of **12** with the known iodo-cyclopentene **13**³⁴ in degassed DMF under Pd₂(dba)₃·CHCl₃ / CuI catalysis, followed by selective protio-desilylation of the TMS-C-acetylene, gave the *ansa*-macrolide precursor **14** in 61% yield, 2 steps. Saponification of **14** afforded the corresponding carboxylic acid. This acid was immediately subjected to Shiina macrolactonization conditions

with 2-methyl-6-nitrobenzoic anhydride (MNBA).^{42,43} These conditions gave the macrolide **15** as a single atropisomer in 62% yield, 2 steps. Mild and selective *N*-Boc deprotection of **15** (via an *O*-TBS carbamate)⁴⁴ and HOAt-mediated⁴⁵ condensation of the free amine **16** with the known naphthoic acid **6** (R= H)³¹ gave the amide **17**. Final treatment of **17** with TBAF, dual *C*- and *O*-trimethylsilylation, and chemoselective C10-*O*-desilylation, gave the L-mycarose C10-*O*-acceptor **18** with its terminal acetylene suitably *C*-protected (thereby minimizing known complications via Ag(I)-complexation).⁴⁰ The alternative treatment of amide **17** with TFA/H₂O (1:2) gave the L-kedarsamine C13-*O*-acceptor **19** with the C4-OH free (thereby improving known reactivity issues).⁴¹

Having the desired macrocyclic glycosyl acceptors in hand, we first examined the reactivity of **18** with L-mycarose (Scheme 3). The C10/C11-*cis* acceptor **18** under established α -selective conditions (AgPF₆/DTBMP) with the thioglycoside **7** failed to yield any 2-deoxypyranoside (**20**). This result could not be overturned and was in contrast to the reactivity of the known C10/C11-*trans* acceptor **21** to give **22**⁴⁰, as well as the success of the AgPF₆/DTBMP glycosylation method during the advanced stages of the total synthesis of the C10-epimer **1'** by the group of Myers.³³ Clearly, the *cis*-facial proximity of the chloropyridyl unit sterically prevented the glycosylation event.

Scheme 3. Glycosylation of C10- α -epimeric alcohol **18** with L-mycarose (**7**).

Next, the glycosylation of the L-kedarsamine Schmidt donor **8** with the C4/C13-diol acceptor **19** was examined (Scheme 4). Initially, our reported α -selective conditions were found unsuccessful, for example, by using BF₃ or TiCl₄ at low or ambient temperatures in chlorinated solvents.⁴¹ Eventually, we succeeded with BF₃·Et₂O in dichloroethane (DCE) at an elevated temperature (40 °C). This gave the desired 2°- α -pyranoside **23** as the minor product (19% isolated yield) in a 1:2 ratio with the 3°-glycoside **24**. As found previously, no glycosylation occurred when the C4-OH group was protected. Such results do not fair well for a total synthesis.

According to these findings, both glycosylations would be better performed at an early-stage of the synthesis (cf. Scheme 1). Such timings would allow for steric hindrances to be

minimized (cf. **3** and **18**; **5** and **19**). In effect, the 2-deoxy- α -pyranoside sugar functionalities may be viewed as elaborate THP protecting groups (Sg^1 , Sg^2) *en route* to constructing a bis-glycosylated enediyne cyclisation precursor (cf. **9**). Although more risky, this strategy offers a more convergent total synthesis of **1**. The acid lability, free hydroxyl and amino functionality, and extra steric potentials of the 2-deoxypyranosides, were thus considered to present additional synthetic challenges (*vide infra*).

Scheme 4. Glycosylation of C4/C13-diol acceptor **19** with L-kedarsamine (**8**).

Undeterred by such challenges, we elected to prepare gram quantities of the C10 and C13 *O*-glycosylated versions of **3** and **5**, respectively (cf. Scheme 1). These fragments would be used later for azatyrosine (**4**) incorporation and Sonogashira coupling studies (*vide infra*). We first targeted the propargyl oxirane moiety **3** as a suitable C10/C11-*trans* glycosyl acceptor (Scheme 5). After a few modifications to established procedures, the iodo-cyclopentenone **25** was prepared as its C10-OTES silyl ether (not as its TBS ether).³⁶ Similar to the protocols of Chemla and Caddick,^{46,47} the allenyl zinc species of 3-chloro-1-trimethylsilylpropyne (prepared at -78 °C) was reacted with the ketone **25** at -18 °C overnight. The crude chlorohydrin **26** was then treated with DBU in dichloromethane to afford the epoxyalkyne **27** stereoselectively in 70% yield, 2 steps. This latter step avoided the use of potassium carbonate,³⁴ so that the TMS-C-protected alkyne **27** could be formed directly. Unlike its C10-OTBS counterpart,³⁴ the TES ether of **27** could also be removed chemoselectively under Brønsted acid conditions to give the desired C10-OH acceptor **3**. Gratifyingly, the thioglycoside **7** reacted smoothly with 2 equivalents of the 2°-alcohol **3** in the presence of $AgPF_6$ /DTBMP.⁴⁰ This furnished the C10/C11-*trans* α -pyranoside **28** exclusively in 81% yield. The excess alcohol **3** was then recovered and recycled. Gram quantities of pure **28** were produced in this manner.

Scheme 5. Synthesis of C10-OH acceptor **3** and α -glycosylation with L-mycarose (**7**).

Next, the gram-scale, α -selective glycosylation of the C13/C4-diol acceptor **5** was pursued with various L-kedarsamine donors **8** (Scheme 6). Due to no silyl acetylene protection, $\text{AgPF}_6/\text{DTBMP}$ conditions were incompatible with **5**.⁴¹ We thus chose NIS/ TfOH to activate the thioglycoside of **8**.⁴⁸ This afforded the 2°- α -pyranoside **29** in a maximum yield of 26 %. Coupling with the alternative glycosyl fluoride of **8** under $\text{Cp}_2\text{HfCl}_2/\text{AgClO}_4$ conditions did not improve yields (15 % at best).^{49,50} Eventually, we found TiCl_4 to be superior to $\text{BF}_3 \cdot \text{Et}_2\text{O}$ in coupling the Schmidt donor **8** and diol **5** under our reported conditions.⁴¹ For scale-up purposes, two-equivalents of diol **5** were used relative to **8**, whereby 0.5 equivalents of TiCl_4 were added under the gentle reflux of CH_2Cl_2 . This rapidly gave the desired 2°- α -pyranoside **29** in a 40% isolated yield. Excess **5** was also recovered (ca. one-equivalent) and all cases produced minor amounts of the 3°- α -pyranoside **30** ($\text{R} = \text{H}$) as an inseparable mixture with **29**. Gratifyingly, all pyranosides **29/30** were found to be α -anomeric ($J = 4.0$ Hz coupling constants). This is consistent with high kinetic control, presumably by virtue of the axial NMe_2 group within an oxocarbenium conformation (**8**→**29**).

Scheme 6. Glycosylation of diol **5** with L-kedarsamine (**8**) and origin of α -selectivity.

Having gram quantities of the L-mycarose and L-kedarsamine fragments **28** and **29** in hand, azatyrosine incorporation of **4** and the search for suitable Sonogashira coupling substrates were explored (Scheme 7). Low temperature, reductive deprotection of the benzoate **28**, by using DIBAL in toluene, thus provided **32**. The *cis*-relative C10/C11-stereochemistry was

next achieved by phenolic Mitsunobu inversion⁵¹ of the allylic C11- β -alcohol **32** by the β -amido-2-chloroazatyrosine **4**. For scale-up purposes, the use of DMEAD was found preferable to DEAD.⁵² Triethylsilyl (TES) protection of the tertiary alcohol on L-mycarose then gave the L-mycarose fragment **34**. Initial attempts at Sonogashira coupling between the iodoalkene **34** and the alkyne **29** or its diol **31** were, however, unproductive. These attempts were in contrast to previous studies with a C13-OMOM equivalent of the L-kedarsamine fragment **29**.³⁴ We therefore decided to explore alternative substrates to achieve this key Sonogashira coupling step.

Scheme 7. Mitsunobu installation of azatyrosine **4** to afford C10/C11-*trans* fragment **33** and attempted Sonogashira coupling between the sugar bearing fragments **34** and **29**.

Scheme 8. Sonogashira coupling and saponification-macrolactonization study.

Additional steric and conformational effects by the kedarosamine moiety were considered the primary causes for the unproductive iodoalkene-alkyne coupling between **29** and **34**. We thus prepared various cyclic diol-protected versions of **29**. These modified substrates **36a–c** proved to be successful under established Pd(0)/Cu(I) Sonogashira conditions (Scheme 8).^{35–38} The orthoester **36c** was selected as the optimal substrate for subsequent hydrolytic, *ansa*-macrolactonization studies. This minimized the loss of acid labile 2-deoxypyranoside moieties during the methanolysis of **37c** to its free diol **38** (82%). The alternative cyclic acetals **37a/b** could not be deprotected cleanly and gave the diol **38** in yields below 55%.^{53,54} Final saponification of **38** and Shiina macrolactonization⁵⁵ generated the atropisomeric *ansa*-macrolide **39** exclusively in 52%, two steps. ROESY NMR analysis between the protons of the pyridyl C4' and epoxy C8 of **39** confirmed its structure. We thus secured a viable route to bis-glycosylated cyclization precursors like **9** (cf. Scheme 1).

Scheme 9. Protecting group selection under Myers' global deprotection conditions.³³

Before progressing forward with **39** and attaching the naphthamide moiety **6**, we became concerned at our protecting group strategy to **1** (cf. Scheme 1). Thus far, relatively strong *O*-TBS protected 2-deoxysugar fragments **34** and **36** were selected. Although useful in establishing the chemistry to advanced *ansa*-macrolides, a final global deprotection sequence to **1** needs to be both rapid and mild due to enediyne instabilities (cf. **10** and **11**). We thus directed our attention to adjusting the protecting groups on the L-mycarose (**7**), L-kedarosamine (**8**) and naphthamide (**6**) moieties. Model substrates **40**, **42**, and **44**¹⁴ were thus prepared and subjected to excess TBAF/*o*-nitrophenol and HF·Et₃N according to Myers' established deprotection sequence to **1'** (Scheme 9).³³ This study demonstrated the clear need for TES protection of the sugar moieties **40** (for R¹) and **42** (for R³) during the end-game of a total synthesis, as well as the need for pivaloyl (Piv) phenolic protection for the naphthamide (**44**). In all these cases, deprotection could be achieved cleanly within 10–30 minutes. In contrast, the TBS ethers of **40** (for R¹) and of **42** (for R³) remained intact even after 3 hours. Bis-TMS protection (R¹, R²) of the mycarose **40** was also found acceptable, but other silyl combinations were not.

Armed with this information and the experience gained in preparing **39**, we turned our attention to assembling a suitably protected version of the advanced intermediate **9** for subsequent enediyne cyclisation studies. After several trials, we settled on making the bis-glycosylated *ansa*-macrolide **50** according to Scheme 10. In this particular case, we began with the TES-protected kedarosamine fragment **46** (freshly prepared) and the TBS-protected mycarose fragment **33** (3°-OH free). After Sonogashira coupling and orthoester methanolysis to diol **47**, the TES ether proximal to NMe₂ was found to cleave during the Shiina macrolactonization step. This generated the *ansa*-macrolide **48**. After TES ether re-protection of the L-kedarosamine moiety of **48**, a chemoselective one-pot amidation procedure was developed. This entailed the sequential addition of TMSOTf/2,6-lutidine, akin to Ohfuné's NH-Boc deprotection conditions,⁴⁴ followed by saturated aqueous sodium bicarbonate solution and the one-pot addition of a preformed CH₂Cl₂ solution of the HOBt-activated naphthoate ester **6**. This afforded the fully protected *ansa*-macrolide **50** in 63% yield from **48**.

Scheme 10. Reliable assembly of a fully protected, storable *ansa*-macrolide (**50**).

Under this scheme, we could reliably prepare 30–90 mg quantities of **50**. Here, samples could be safely stored as dilute CH₂Cl₂ solutions at –20 °C over a couple of months. When required, a suitably protected aldehyde substrate would thus be prepared for immediate enediyne cyclization studies. Preparations of the mono-TES (**54**) and bis-TMS (**55**) protected aldehydes are given in Scheme 11. After complete TBAF deprotection of **50** to its unstable pentaol, care was needed to achieve the differential Piv, TES, and TMS *O*-protection pattern as achieved in **51** and **52**. In one-pot operations, mono-pivalation of the naphtholic group was first effected at –78 °C with PivCl. Next, mono-triethylsilylation of the kedarsoamine moiety was effected at 0 °C. This was followed by either mono-TES or bis-TMS silylation of the

mycarose moiety in the presence of cat. DMAP. Ultimately, in the same pot, the C4-OH was protected as its TMS ether. Subsequent treatment of **51/52** with DDQ resulted in the *N*-demethylated alcohol **53**. Although the oxidative *N*-methyl cleavage process could not be circumvented, crude **53** was readily *N*-methylated under reductive amination conditions using formalin and NaBH₃CN. Dess-Martin periodinane (DMPI) oxidation of the primary alcohol then delivered the aldehydes **54** and **55** in good overall yields (75–90 % over 3 steps).

Scheme 11. Preparation of aldehyde enediyne cyclisation precursors (**54/55**).

The formidable challenges to transform multicyclic alkyne-aldehydes like **54/55** into fully fledged, epoxybicyclo[7.3.0]-dodecadienediyne cores should not be underestimated by any means. Whilst the aldehydes themselves are considered unstable in traditional senses, once the nine-membered enediyne cores are forged closed, all subsequent synthetic operations and characterization studies should be ideally performed within 16 hours, especially for kedarcidin-based chromophores. All reagents, methods and work-up operations need to be mild, streamlined and rapid in both chemical and practical senses. After considerable experimentation and refinement of reaction timings and bench skills, a 6-step sequence to **1** was eventually shown to be viable over a total time period of 12-hours (Scheme 12). This entailed the cyclisation of the enediyne-aldehydes **54/55** via the highly unstable *cis*-diol derivatives **58–63** and SmI₂-based reductive transformation into the equally unstable epoxy-dienediynes **64–69** (Table 1).

Scheme 12. Nine-membered enediyne cyclisation and end-game sequence to **1**.

Table 1. End-game olefination-deprotection sequence to kedarcidin chromophore (**1**).

Entry ^[a]	R ¹ , R ² , R ³ , R ⁴	$\Delta\text{HRMS}^{[b]}$	t (TBAF / HF) ^[c]	1 ^[d]
58 → 64	TES, H, TES, Ms	0.0015	10 / 2 min	nd
59 → 65	TBS, H, TES, Ms	nd	10 / 5 min	nd
60 → 66	TMS, H, TES, Ms	nd	10 / 2 min	nd
61 → 67	TBS, TES, TBS, Ms	0.0004 ^[e]	10 / 5 min	nd
62 → 68	TMS, TMS, TES, Ms	0.0002	10 / 25 min	2% ^[f]
63 → 68	TMS, TMS, TES, TFBz	0.0001	10 / 20 min	3% ^[f]

[a] All entries were repeated twice; see Scheme 12 and Supporting Information for conditions of preparation. [b] Difference between calculated and found HRMS data for **64–69** after treatment of **58–66** with SmI₂ in THF at –20 °C for 5–10 min. [c] Respective times of treatments with TBAF/o-nitrophenol and then HF-pyridine. [d] nd = not detected. [e] Cycloaromatized product from **67** had an HRMS difference of 0.005 after treatment with cyclohexa-1,4-diene in THF over 22 h. [f] Relative percentage of **1** to the major (100%) species observed by HRMS: 1030.3734 calculated for [M+H]⁺ = [C₅₃H₆₁ClN₃O₁₆]⁺, found 1030.3732 (from **62** via **68**) and 1030.3733 (from **63** via **68**).

Specifically, nine-membered epoxy-enediynes **54/55** using $\text{CeCl}_3/\text{LiHMDS}$ to give the C4→C5 *O*-migrated TMS products **56/57** necessitated careful quenching with phosphate buffer (pH 7) at -78°C . The resulting products **56/57** were treated with TBAF carefully at -78°C to remove the C5-*O*-TMS group. For the *cis*-C4,C5-diol mesylate derivatives (**58–62**), desilylation was immediately followed by mesylate formation and then esterification with *p*-trifluoromethylbenzoyl (TfBz) chloride. The bis-OTMS, bis-OTfBz substrate (**63**) was also prepared by omitting the mesylation step. This proved to be more time economical, but **63** was found to be more unstable than its C5-OMs counterpart (**62**). It should be noted that electron withdrawing C4,C5-diol substituents marginally reduce the propensity of nine-membered cores from undergoing oxy-Cope like sigmatropic rearrangements.^{35,37} Nevertheless, all enediyne cores **58–62** remained highly unstable to all silica gel chromatography techniques and all work-up operations. As a result, we were only able to obtain high resolution mass spectroscopic (HRMS) data for all compounds in Scheme 12 (cf. Table 1).

Further discussion is necessary for these final olefination-deprotection studies. Thus, all cyclized C4,C5-diol mesylate derivatives **58–63** were first subjected to reductive olefination by SmI_2 at -20°C to afford the fully-fledged epoxydienediynes **64–69** (Table 1).^{38,56,57} After HRMS data collection, these were immediately subjected to the established global deprotection conditions, namely, by brief exposure with TBAF/*o*-nitrophenol and then exposure to $\text{HF-Et}_3\text{N}$ over differing time scales (cf. Scheme 9). Whilst the TBS-protected mesylate derivatives **59/60** conferred the greatest stabilities, these could not be transformed to **1**. The protected and cycloaromatized forms of **1** were, however, detected by HRMS analysis of **67** before and after treatment with cyclohexa-1,4-diene in THF (cf. Table 1). Interestingly, the more successful derivatives **61–63** all featured bis-silyl ether protection on the mycarose moiety. These derivatives all gave accurate HRMS data correlations after SmI_2 olefination to **67–69**. We thus suspected complexation/activation issues from samarium(II/III)-salts, but additives like pyridine and 2,6-lutidine during work-up procedures (prior to filtration through Celite) did not improve the results. Ultimately, after exhaustive use of the advanced precursor **50**, the bis-TMS ethers **62** or **63** gave an accurate match of the HRMS data patterns for **1**, albeit in relatively low percentages. A viable total synthesis route to the kedarcidin chromophore was thus identified for the first time in our laboratories.

Conclusion

Herein, we have disclosed our concerted efforts towards securing a total synthesis of the latest revised structure of the kedarcidin chromophore **1** (cf. Scheme 1).^{33,34} Initial glycosylation studies demonstrated the poor reactivity of late-stage aglycon acceptors like **18** and **19** (cf. Schemes 2 to 4). Consequently, pre- α -glycosylated fragments of the epoxy-iodoalkene **33** and alkyne-orthester **44** were prepared on gram scales by reworking previously developed chemistry (cf. Schemes 5 to 8).^{34–38} These fragments were then assembled after optimization of Sonogashira coupling,⁵⁸ Shiina macrolactonization,⁵⁵ and mixed-anhydride amidation protocols.⁴⁵ These efforts eventually furnished the *ansa*-macrolide **50** as a storable substrate that is fully-adorned with all the components of the kedarcidin chromophore (cf. Scheme 10).

During latter enediyne cyclisation studies, our protecting group strategy was assessed for its potential to succeed at the last step of the synthesis. This highlighted the need for either mono-TES or bis-TMS ether protection of the 2-deoxysugar moieties (cf. Scheme 9). The alkyne-aldehyde cyclization precursors **54/55** were thus prepared in appropriately protected

forms (cf. Scheme 11). The subsequent development of a streamlined cyclisation-derivatisation-deprotection sequence to the fully-fledged, nine-membered enediyne proved to be extraordinarily challenging on the bench (cf. Scheme 12). After exhaustive trials and tribulations, the bis-OTMS ether **55** (freshly prepared from **50**) was first cyclized to **56/57** under Ce(III)-amide mediation, then derivatized as its C4-*O*-trifluorobenzoate (TfBz) ester **62** or **63**, deoxygenated by SmI₂ to its olefin **68**, and finally deprotected under buffered fluoride conditions to afford the kedarcidin chromophore (**1**), as inferred by HRMS analysis (cf. Table 1).

To close this paper, we note that the early introduction of 2-deoxy- α -pyranosides as elaborate THP protecting groups offered a convergent route to **1**. Accordingly, a viable total synthesis strategy was founded in only 17-steps via the equally convergent synthesis of suitably protected L- α -mycaroside (**33**) and L- α -kedarosaminide (**44**) fragments. This result is meaningful for a target of this complexity and fragility, and was achieved in spite of the additional challenges imposed by free hydroxyl/amino-groups and extra bulky/labile-functionality. At the root of our tactical and evolutionary pursuit of this formidable natural product were the development of several powerful, yet chemoselective methods. Over 20-years since kedarcidin was isolated and first characterized,^{24–30} several new synthetic organic methods may now be highlighted, namely: Myers' anionic transannular cyclization,³³ stereoselective epoxyalkyne formation,³⁴ atropselective Pd/Cu-Sonogashira coupling,^{36–38} 2-deoxy- α -glycosylation,^{40,41} CeX₃-mediated enediyne cyclisation,¹⁴ and SmI₂-based reductive olefination.^{56,57} Further application of some of these key methods to the synthesis of the putative biomimetic enediyne-precursors of the fijiolides will be reported in due course.²¹

Experimental Section: see SI

Acknowledgements: This work represents over 20-years of collective effort (1997–2017) and was latterly supported by a Grant-in-Aid for Specially Promoted Research from the Ministry of Education, Culture, Sports, Science, and Technology (MEXT), SORST (Japan), as well as the Science and Technology Agency (JST), Japanese Society for the Promotion of Science Fellowship and Multidimensional Materials Science Leaders Program (to M.J.L.). We are especially grateful to Dr. John E. Leet at Bristol-Myers Squibb for kindly providing original chromoprotein material and the ¹H NMR spectra of the natural kedarcidin chromophore.

References

1. *Observations in the Chemistry and Biology of Cyclic Enediyne Antibiotics: Total Syntheses of Calicheamicin γ II and Dynemicin A*, S. J. Danishefsky, M. D. Shair, *J. Org. Chem.* **1996**, 61, 16.
2. *The enediyne antibiotics*, A. L. Smith, K. C. Nicolaou, *J. Med. Chem.* **1996**, 39, 2103.
3. *DNA damaging enediyne compounds*, Z. Xi, I. H. Goldberg in *Comprehensive Natural Product Chemistry*, Vol. 7 (Eds.: D. H. R. Barton, K. Nakanishi), Pergamon, Oxford, **1999**, p. 553.
4. *Mechanisms of in situ activation for DNA-targeting antitumor agents*, S. E. Wolkenberg, D. L. Boger, *Chem. Rev.* **2002**, 102, 2477
5. *Antitumor antibiotics: bleomycin, enediynes, and mitomycin*, U. Glam, M. H. Hager, S. G. Van Lanen, J. Ju, J. S., Thorson, B. Shen, *Chem. Rev.* **2005**, 105, 739
6. *Enediynes*, P. R. Hamann, J. Upešlaciš, D. B. Borders, in *Anticancer Agents from Natural Products*, ed. G. M. Cragg, G. G. I. Kingston, D. J. Newman, CRC Press, 2nd edn, **2011**, pp. 575–621.

- 434 7. *Design and Synthesis of Neocarzinostatin Analogues*, M. Hirama, *J. Synth. Org. Chem.*
435 *Jpn.* **1991**, 49, 1032.
- 436 8. *Chemistry and Biology of the Eneidyne Anticancer Antibiotics*, K. C. Nicolaou, W.-M. Dai,
437 *Angew. Chem., Int. Ed. Engl.* **1991**, 30, 1387.
- 438 9. *The enediyne and dienediyne based antitumour antibiotics. Methodology and strategies for*
439 *total synthesis and construction of bioactive analogues. Part 2*, H. Lhermitte, D. S. Grierson,
440 *Contemp. Org. Synth.* **1996**, 3, 93.
- 441 10. *The chemistry of enediynes, enyne allenes and related compounds*, J. W. Grissom, G. U.
442 Gunawardena, D. Klingberg, D. Huang, *Tetrahedron* **1996**, 52, 6453.
- 443 11. *The bis (enol triflate) route to dienediyne models of the biradical forming and DNA-*
444 *cleaving natural product neocarzinostatin chromophore*, R. Brückner, J. Suffert, *Synlett*
445 **1999**, 657
- 446 12. *Recent Advances in the Synthetic Studies of Nine-membered Eneidyne Antitumor*
447 *Antibiotics*, I. Sato, M. Hirama, *J. Synth. Org. Chem., Jpn.* **2010**, 68, 1123.
- 448 13. *The first total synthesis of N1999-A2: absolute stereochemistry and stereochemical*
449 *implications into DNA cleavage*, S. Kobayashi, S. Ashizawa, Y. Takahashi, Y. Sugiura, M.
450 Nagaoka, M. J. Lear, M. Hirama, *J. Am. Chem. Soc.* **2001**, 123, 11294.
- 451 14. *Synthesis and Characterization of Nine-Membered Cyclic Eneidiynes, Models of the C-*
452 *1027 and Kedarcidin Chromophores: Equilibration with a p-Benzyne Biradical and Kinetic*
453 *Stabilization*, K. Iida, M. Hirama, *J. Am. Chem. Soc.* **1995**, 117, 8875
- 454 15. *Synthesis and chemistry of chromoprotein antitumor antibiotics: Nine-membered*
455 *enediynes are equilibrated with p-benzyne type biradicals*, M. Hirama, *Pure Appl. Chem.*
456 **1997**, 69, 88
- 457 16. *Evidence for facile atropisomerism and simple (non-nucleophilic) biradical-forming*
458 *cycloaromatization within kedarcidin chromophore aglycon*, A. G. Myers, A. R. Hurd, P. C.
459 Hogan, *J. Am. Chem. Soc.* **2002**, 124, 4583.
- 460 17. *Spin Trapping of ¹³C-Labeled p-Benzynes Generated by Masamune–Bergman Cyclization*
461 *of Bicyclic Nine-Membered Eneidiynes*, T. Usuki, T. Mita, M. J. Lear, P. Das, F. Yoshimura,
462 M. Inoue, M. Hirama K. Akiyama, S. Tero-Kubota, *Angew. Chem. Int. Ed.* **2004**, 43, 5249
- 463 18. *Direct observation of ESR spectra of bicyclic nine-membered enediynes at ambient*
464 *temperature*, M. Hirama, K. Akiyama, P. Das, T. Mita, M. J. Lear, K.-i. Iida, I. Sato, F.
465 Yoshimura, T. Usuki, S. Tero-Kubota, *Heterocycles* **2006**, 69, 83-89.
- 466 19. *When the nine-membered enediynes play hide and seek*, M. Jean, S. Tomas, P. van de
467 Weghe, *Org. Biomol. Chem.* **2012**, 10, 7453
- 468 20. *Total synthesis of sporolide B*, K. C. Nicolaou, Y. Tang, J. Wang, *Angew. Chem. Int. Ed.*
469 **2009**, 48, 3449.
- 470 21. *Fijiolides A and B, Inhibitors of TNF- α -Induced NF κ B Activation, from a Marine-*
471 *Derived Sediment Bacterium of the Genus Nocardiosis*, S.-J. Nam, S. P. Gaudêncio, C. A.
472 Kauffman, P. R. Jensen, T. P. Kondratyuk, L. E. Marler, J. M. Pezzuto, W. Fenical, *J. Nat.*
473 *Prod.* **2010**, 73, 1080.
- 474 22. *Cyanosporasides A and B, Chloro- and Cyano-cyclopenta[a]indene Glycosides from the*
475 *Marine Actinomycete “Salinispora pacifica”*, D.-C. Oh, P. G. Williams, C. A. Kauffman,
476 P. R. Jensen, W. Fenical, *Org. Lett.* **2006**, 8, 1021.
- 477 23. *Biomimetic Total Synthesis of Cyanosporaside Aglycons from a Single Eneidyne*
478 *Precursor through Site-Selective p-Benzyne Hydrochlorination*, K. Yamada, M. J. Lear, T.
479 Yamaguchi, S. Yamashita, I. D. Gridnev, Y. Hayashi, M. Hirama, *Angew. Chem. Int. Ed.*
480 **2014**, 53, 13902.
- 481 24. *Kedarcidin, a new chromoprotein antitumor antibiotic. I. Taxonomy of producing*
482 *organism, fermentation and biological activity*, S. Lam, G. A. Hesler, D. R. Gustavson, A. R.
483 Crosswell, J. M. Veitch, S. Forenza, K. Tomita, *J. Antibiot.* **1991**, 44, 472.

- 484 25. Kedarcidin, a new chromoprotein antitumor antibiotic, S. J. Hofstend, J. A. Matson, A.
485 R. Malacko, H. Marquardt, *J. Antibiot.* **1992**, 45, 1250.
- 486 26. Cloning and sequencing of the kedarcidin biosynthetic gene cluster from
487 *Streptoalloteichus* sp. ATCC 53650 revealing new insights into biosynthesis of the enediyne
488 family of antitumor antibiotics, J. R. Lohman, S.-X. Huang, G. P. Horsman, P. E. Dilfer, T.
489 Huang, Y. Chen, E. Wendt-Pienkowskib, B. Shen, *Mol. BioSyst.*, **2013**, 9, 478.
- 490 27. Kedarcidin, a new chromoprotein antitumor antibiotic: structure elucidation of
491 kedarcidin chromophore, J. E. Leet, D. R. Schroeder, S. J. Hofstead, J. Golik, K. L. Colson,
492 S. Huang, S. E. Klohr, T.W. Doyle, J. A. Matson, *J. Am. Chem. Soc.* **1992**, 114, 7946
- 493 28. Chemistry and structure elucidation of the kedarcidin chromophore, J. E. Leet, D. R.
494 Schroeder, D. R. Langley, K. L. Colson, S. Huang, S. E. Klohr, M. S. Lee, J. Golik, S. J.
495 Hofstead, T. W. Doyle, J. A. Matson, *J. Am. Chem. Soc.* **1993**, 115, 8432; [Erratum], *J. Am.*
496 *Chem. Soc.* **1994**, 116, 2233.
- 497 29. Sequential ^1H , ^{13}C , and ^{15}N -NMR Assignments and Solution Conformation of
498 Apokedarcidin, K. L. Constantine, K. L. Colson, M. Wittekind, M. S. Friedrichs, N. Zein, J.
499 Tuttle, D. R. Langley, J. E. Leet, D. R. Schroeder, K. S. Lam, B. T. Farmer II, W. J. Metzler,
500 R. E. Bruccole, L. Mueller, *Biochemistry* **1994**, 33, 11438–11452.
- 501 30. Selective proteolytic activity of the antitumor agent kedarcidin, N. Zein, A. M. Casazza,
502 T. W. Doyle, J. E. Leet, D. R. Schroeder, W. Solomon, S. G. Nadler, *Proc. Natl. Acad. Sci.*
503 *USA* **1993**, 90, 8009.
- 504 31. Synthetic study of kedarcidin chromophore: revised structure, S. Kawata, S. Ashizawa,
505 M. Hirama, *J. Am. Chem. Soc.* **1997**, 119, 12012.
- 506 32. A new member of the 4-methylideneimidazole-5-one-containing aminomutase family from
507 the enediyne kedarcidin biosynthetic pathway, S.-X. Huang, J. R. Lohmana, T. Huang, B.
508 Shen, *Proc. Nat. Acad. Sci.* **2013**, 110, 8069.
- 509 33. Kedarcidin chromophore: synthesis of its proposed structure and evidence for a
510 stereochemical revision, F. Ren, P. C. Hogan, A. J. Anderson, A. G. Myers, *J. Am. Chem.*
511 *Soc.* **2007**, 129, 5381.
- 512 34. Total synthesis of a protected aglycon of the kedarcidin chromophore, K. Ogawa, Y.
513 Koyama, I. Ohashi, I. Sato, M. Hirama, *Angew. Chem. Int. Ed.* **2009**, 48, 1110.
- 514 35. Synthesis of ^{13}C -labelled, bicyclic mimetics of natural enediynes, P. Das, T. Mita, M. J.
515 Lear, M. Hirama, *Chem. Commun.* **2002**, 2624.
- 516 36. Efficient construction of the kedarcidin chromophore ansamacrolide, Y. Koyama, M. J.
517 Lear, F. Yoshimura, I. Ohashi, T. Mashimo, M. Hirama, *Org. Lett.* **2005**, 7, 267.
- 518 37. Synthesis of the entire carbon framework of the kedarcidin, F. Yoshimura, M. J. Lear, I.
519 Ohashi, Y. Koyama, M. Hirama, *Chem. Commun.* **2007**, 3057.
- 520 38. Secure route to the epoxybicyclo[7.3.0]dodecadienediyne core of the kedarcidin
521 chromophore, K. Ogawa, Y. Koyama, I. Ohashi, I. Sato, M. Hirama, *Chem. Commun.* **2008**,
522 6327.
- 523 39. Convenient route to derivatives of the 2-deoxysugar subunits of the kedarcidin
524 chromophore: L-mycarose and L-kedarosamine, M. J. Lear, M. Hirama, *Tetrahedron Lett*
525 **1999**, 40, 4897.
- 526 40. A Direct and Efficient α -Selective Glycosylation Protocol for the Kedarcidin Sugar, L-
527 Mycarose: AgPF₆ as a Remarkable Activator of 2-Deoxythioglycosides, M. J. Lear, F.
528 Yoshimura, M. Hirama, *Angew. Chem. Int. Ed.* **2001**, 40, 946
- 529 41. Use of Polystyrene-Supported DBU in the Synthesis and α -Selective Glycosylation Study
530 of the Unstable Schmidt Donor of L-Kedarosamine, I. Ohashi, M. J. Lear, F. Yoshimura, M.
531 Hirama, *Org. Lett.* **2004**, 6, 719.

42. A New Condensation Reaction for the Synthesis of Carboxylic Esters from Nearly Equimolar Amounts of Carboxylic Acids and Alcohols Using 2-Methyl-6-nitrobenzoic Anhydride, I. Shiina, R. Ibuka, M. Kubota, *Chem. Lett.* **2002**, 286.
43. A novel and efficient macrolactonization of ω -hydroxycarboxylic acids using 2-methyl-6-nitrobenzoic anhydride (MNBA), I. Shiina, M. Kubota, R. Ibuka, *Tetrahedron Lett.* **2002**, 43, 7535.
44. Syntheses and reactions of silyl carbamates. 1. Chemoselective transformation of amino protecting groups via tert-butyldimethylsilyl carbamates, M. Sakaitani, Y. Ohfuné, *J. Org. Chem.* **1990**, 55, 870.
45. 1-Hydroxy-7-azabenzotriazole. An efficient peptide coupling additive, L. A. Carpino, *J. Am. Chem. Soc.* **1993**, 115, 4397.
46. Preparation of Propargylic Carbenoids and Reactions with Carbonyl Compounds – A Stereoselective Synthesis of Propargylic Halohydrins and Oxiranes, F. Chemla, N. Bernard, F. Ferreira, J. F. Normant, *Eur. J. Org. Chem.* **2001**, 3295.
47. An efficient synthesis of epoxydienes and a key fragment of neocarzinostatin chromophore, J. R. Baker, O. Thominet, H. Britton, S. Caddick, *Org. Lett.* **2007**, 9, 45.
48. A convenient, one-step, high-yield replacement of an anomeric hydroxyl group by a fluorine atom using DAST. Preparation of glycosyl fluorides, G. H. Posner, S. R. Haines, *Tetrahedron Lett.* **1985**, 26, 5.
49. New glycosidation reaction 1: Combinational use of $\text{Cp}_2\text{ZrCl}_2\text{-AgClO}_4$ for activation of glycosyl fluorides and application to highly β -selective glycosidation of D-mycinoise, T. Matsumoto, H. Maeta, K. Suzuki, G. Tsuchihashi, *Tetrahedron Lett.* **1988**, 29, 3567.
50. New glycosidation reaction 2. Preparation of 1-fluoro-D-desosamine derivative and its efficient glycosidation by the use of $\text{Cp}_2\text{HfCl}_2\text{-AgClO}_4$ as the activator, K. Suzuki, H. Maeta, T. Matsumoto, G. Tsuchihashi, *Tetrahedron Lett.* **1988**, 29, 3571.
51. The use of diethyl azodicarboxylate and triphenylphosphine in synthesis and transformation of natural products, O. Mitsunobu, *Synthesis* **1981**, 1.
52. Di-2-methoxyethyl azodicarboxylate (DMEAD): An inexpensive and separation-friendly alternative reagent for the Mitsunobu reaction, T. Sugimura, K. Hagiya, *Chem. Lett.* **2007**, 36, 566.
53. 4-(tert-Butyldimethylsilyloxy) benzylidene acetal: a novel benzylidene-type protecting group for 1, 2-diols, Y. Kaburagi, H. Osajima, K. Shimada, H. Tokuyama, T. Fukuyama, *Tetrahedron Lett.* **2004**, 19, 3817.
54. Novel Para-Substituted Benzyl Ethers for Hydroxyl Group Protection, L. Jobron, O. Hindsgaul, *J. Am. Chem. Soc.* **1999**, 121, 5835.
55. An Effective Use of Benzoic Anhydride and Its Derivatives for the Synthesis of Carboxylic Esters and Lactones: A Powerful and Convenient Mixed Anhydride Method Promoted by Basic Catalysts, I. Shiina, M. Kubota, H. Oshiumi, M. Hashizume, *J. Org. Chem.* **2004**, 69, 1822.
56. Total Synthesis of the Maduropeptin Chromophore Aglycon, K. Komano, S. Shimamura, M. Inoue, M. Hirama, *J. Am. Chem. Soc.* **2007**, 129, 14184.
57. Total synthesis of the C-1027 chromophore core: extremely facile enediyne formation through Sml_2 -mediated 1,2-elimination, M. Inoue, I. Ohashi, T. Kawaguchi, M. Hirama, *Angew. Chem. Int. Ed.* **2008**, 47, 1777.
58. A Convenient Synthesis of Acetylenes: Catalytic Substitutions of Acetylenic Hydrogen with Bromoalkenes, Iodoarenes and Bromopyridines, K. Sonogashira, Y. Tohda, N. Hagihara, *Tetrahedron Lett.* **1975**, 16, 4467.